Symyx Technologies
   HOME

TheInfoList



OR:

Symyx Technologies, Inc. was a company that specialized in informatics and automation products. Symyx provided software solutions for scientific research, including Enterprise Laboratory Notebooks and products for
combinatorial chemistry Combinatorial chemistry comprises chemical synthetic methods that make it possible to prepare a large number (tens to thousands or even millions) of compounds in a single process. These compound libraries can be made as mixtures, sets of individua ...
. The software part of the business became part of
Accelrys BIOVIA is a software company headquartered in the United States, with representation in Europe and Asia. It provides software for chemical, materials and bioscience research for the pharmaceutical, biotechnology, consumer packaged goods, aerospa ...
, Inc. in 2010 and then in 2014 this company merged with
Dassault Systèmes Dassault Systèmes SE () (abbreviated 3DS) is a French software corporation which develops software for 3D product design, simulation, manufacturing and other 3D related products. Founded in 1981, it is headquartered in Vélizy-Villacoublay, F ...
. Symyx also offered laboratory robotics systems for performing automated chemical research, which in 2010 was spun out as Freeslate, Inc.


Products

Symyx offered high-speed combinatorial technologies for the discovery of new materials. Using proprietary technologies - including instruments, software and methods - Symyx was able to generate hundreds to thousands of unique materials at a time and screen those materials rapidly and automatically for desired properties. This approach was said to deliver results hundreds to thousands of times faster than traditional research methods, at a fraction of the cost. Symyx applied this technology to revolutionize materials discovery in the life sciences, chemical, and electronics industries.


History

Founded in 1994 by Dr.
Alejandro Zaffaroni Alejandro Zaffaroni (February 27, 1923 – March 1, 2014) was a Uruguayan serial entrepreneur who was responsible for founding several biotechnology companies in Silicon Valley. Products that he was involved in developing include the birth contr ...
and Dr.
Peter G. Schultz Peter G. Schultz (born June 23, 1956) is an American chemist. He is the CEO and Professor of Chemistry at The Scripps Research Institute, the founder and former director of GNF, and the founding director of the California Institute for Biomedi ...
, Symyx' conceptual basis drew from Affymax, Inc. and Affymetrix, Inc., which commercialized the use of high-speed combinatorial methods for
pharmaceutical A medication (also called medicament, medicine, pharmaceutical drug, medicinal drug or simply drug) is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field an ...
and genetic research, respectively. Dr. Eric McFarland, professor at UCSB, was the founding director. Symyx screens about a million materials a year and has produced a product pipeline with several materials that have the potential to be commercialized in the next few years. Examples of their discovery efforts include X-ray storage phosphors for radiography, polymers to speed DNA research and catalysts for the manufacture of pharmaceuticals, chemicals and plastics. In 2004, Symyx Technologies acquired Intellichem, a software manufacturer for
electronic laboratory notebook An electronic lab notebook (also known as electronic laboratory notebook, or ELN) is a computer program designed to replace paper laboratory notebooks. Lab notebooks in general are used by scientists, engineers, and technicians to document resear ...
s and, in 2007 Symyx Technologies acquired MDL Information Systems (originally Molecular Design Limited, Inc.), a provider of R&D informatics in the chemistry and life sciences industries, which had been launched as a computer-aided drug design firm in January 1978. With this purchase came the purveyorship of the
Centers for Disease Control and Prevention The Centers for Disease Control and Prevention (CDC) is the national public health agency of the United States. It is a United States federal agency, under the Department of Health and Human Services, and is headquartered in Atlanta, Georgi ...
- NIOSH
Registry of Toxic Effects of Chemical Substances Registry of Toxic Effects of Chemical Substances (RTECS) is a database of toxicity information compiled from the open scientific literature without reference to the validity or usefulness of the studies reported. Until 2001 it was maintained by U ...
(RTECS, www.cdc.gov/niosh/rtecs), a database of basic toxicity information on household chemical substances, food additives, drugs, solvents, biocides, and chemical waste components which as of first quarter of 2012 contained ≈170,000 entries. In 2008, Symyx sold non-RTECS portions of the occupational health and safety (OHS) component of the MDL business to ChemAdvisor, Inc., of Pittsburgh, Pennsylvania. Subsequent innovations derived from these business components included an enterprise
electronic laboratory notebook An electronic lab notebook (also known as electronic laboratory notebook, or ELN) is a computer program designed to replace paper laboratory notebooks. Lab notebooks in general are used by scientists, engineers, and technicians to document resear ...
(ELN) capable of supporting multiple scientific disciplines. In 2010 Symyx spun off their laboratory robotics business as Freeslate, Inc. Freeslate developed high throughput systems for automating chemical research. In 2010, the remaining Symyx software business merged with
Accelrys BIOVIA is a software company headquartered in the United States, with representation in Europe and Asia. It provides software for chemical, materials and bioscience research for the pharmaceutical, biotechnology, consumer packaged goods, aerospa ...
, with the combined company being known simply as Accelrys. In 2014, Accelrys in turn merged with Dassault Systèmes, who announced the creation of the BIOVIA brand to supply software for scientific applications.


Business model considerations

The concept of combinatory chemistry (outside of bio-tech area) was the focus of Symyx. The initial Symyx business model was to provide contract research for large chemical companies at a contract size from $0.5 Million to $200 Million. The company had initial success in gaining enough contracts to reach profitability, with small deals with few initial customers which led to large deals, such as with Exxon. Symyx then started to sell equipment. One other key point was the company had to develop new tools and hire new people when a new project came up because the contract was in a brand new research area and required different expertise. Therefore, the research contract business was not scalable. This is seen as the reason for company failure, even though the company had over 500 patents. Other companies followed Symyx's path. Intermolecular licensed Symyx patents on electronic materials and is developing tools for the electronic materials companies.


References

{{Reflist


External links


Official website as BIOVIA/Dassault Systèmes
Chemical companies of the United States Software companies based in California Technology companies based in the San Francisco Bay Area Companies based in Santa Clara, California Software companies established in 1994 1994 establishments in California American companies established in 1994 Software companies of the United States